As more agents approach the clinic, it is imperative for researchers to consider the design and conduct of immuno-oncology clinical trials. Given the diversity of agents in this newly tapped field, researchers may encounter unique challenges for site selection, patient selection, biomarker selection and imaging for assessing patient responses.
Read More
Medpace Imaging Core Laboratory, Associate Director, Dr. Scott Holland, had an opportunity to sit down with Dr. Bashir to discuss all things NASH imaging. In the interview, they discuss his experience with imaging biomarkers for use in clinical trials for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH).
Read More
Dr. Sharmila Majumdar discusses the opportunities and challenges of rheumatoid arthritis imaging with Scott Holland, PhD, Associate Director of Medpace Imaging Core Laboratory, in this timely and relevant interview.
Read More
Medpace Core Laboratories welcomed Alexia Daoust, PhD to its project management team in Lyon, France. She is a neurobiologist with over seven years of experience in leading and managing complex, high-level research projects. We recently sat down with Dr. Daoust and asked her what attracted her to the Medpace model and where she thinks the innovations in the field of imaging will be.
Read More
Medpace Imaging Core Lab has experience and expertise in autoimmune imaging using conventional and molecular imaging methods.
Read More
Ophthalmology is a growing therapeutic area in clinical research with new and exciting developments occurring in the field, particularly in stem cell and gene cell therapies. Marco Tangelder, MD, Senior Medical Director, Medical department at Medpace highlights some of the advancements in Ophthalmology research and where the field is headed.
Read More
In our previous post, we discussed the approaches to help you identify, enroll and retain rare disease populations in clinical trials. Once the right patients have been enrolled in the trial, the challenge becomes measuring the efficacy of the experimental treatment and determining whether it’s producing the desired effect. However, invasive drug delivery methods, such as IV injection, can complicate this measurement and establishing whether the therapy actually reaches the target tissue can be difficult.
Read More